Immunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast Cancer

World News: . []

MORRIS PLAINS, N.J., May 16, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a science-based and innovation-focused biopharmaceutical company committed to the development and worldwide commercialization of its unique and proprietary antibody-drug conjugate (ADC) platform, today announced that sacituzumab govitecan, its lead investigational ADC, induced promising objective responses as a single agent in heavily pre-treated patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).

“For women with HR+ metastatic breast cancer relapsing after endocrine treatment, there are currently limited treatment options,” said Aditya Bardia, MD, MPH, Director of Precision Medicine and attending physician at Center for Breast Cancer, Massachusetts General Hospital, Harvard Medical School, Boston, MA and lead author of the abstract. “I am very encouraged with the results of sacituzumab govitecan in this subgroup of patients with metastatic breast cancer.”

As reported in the ASCO abstract released online on May 16, 2018, sacituzumab govitecan generated a confirmed overall response rate (ORR) of 31 percent in heavily pre-treated ER+/HER2- mBC patients (N = 54), based on local assessment. The six-month clinical benefit rate was 48 percent.

“We are extremely encouraged to see that our unique ADC is showing promise as a treatment for the ER+/HER2- subgroup, providing further evidence in establishing sacituzumab govitecan as a foundational therapy for metastatic breast cancer,” said Dr. Robert Iannone, Head of Research & Development and Chief Medical Officer of Immunomedics.

Sacituzumab govitecan treatment was generally well tolerated, with no treatment-related deaths. Consistent with safety data obtained in metastatic TNBC, grade 3 or 4 toxicity with greater than 10 percent frequency included neutropenia and leukopenia. There was one case of grade 3/4 diarrhea and febrile neutropenia.

Additional findings, including durability of responses and patient sub-group analyses will be presented in an oral session at 9:12 a.m. (Central Time) on Sunday, June 3, 2018 at the ASCO meeting:

More news and information about Immunomedics, Inc.

Published By:

Globe Newswire: 22:01 GMT Wednesday 16th May 2018

Published: .

Search for other references to "immunomedics" on SPi News

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us

Advertising on SPi News: Information For Advertisers